Apyx Medical Corp APYX
We take great care to ensure that the data presented and summarized in this overview for Apyx Medical Corp is accurate and up-to-date, based on a comprehensive analysis of 13F filing forms for institutional ownership and form 4 filings for insider transactions. Please note that this data may differ from other sources and should not be relied upon as the sole basis for investment decisions.
Top Institutions Holding APYX
View all-
Archon Capital Management LLC Seattle, WA3.45MShares$4.87 Million1.62% of portfolio
-
Royce & Associates LP2.44MShares$3.44 Million0.03% of portfolio
-
Vanguard Group Inc Valley Forge, PA1.48MShares$2.09 Million0.0% of portfolio
-
Invenire Partners, LP Ridgefield, CT946KShares$1.33 Million100.0% of portfolio
-
Taylor Frigon Capital Management LLC638KShares$899,1710.42% of portfolio
-
Silverberg Bernstein Capital Management LLC Armonk, NY621KShares$876,1550.83% of portfolio
-
Horizon Kinetics Asset Management LLC615KShares$867,1500.02% of portfolio
-
Cowen Prime Advisors LLC606KShares$854,0111.06% of portfolio
-
Black Rock Inc. New York, NY500KShares$704,3920.0% of portfolio
-
Commonwealth Equity Services, LLC497KShares$700,8820.0% of portfolio
Latest Institutional Activity in APYX
Top Purchases
Top Sells
About APYX
Apyx Medical Corporation, an energy technology company, develops, manufactures, and sells medical devices in the cosmetic and surgical markets worldwide. The company operates in two segments, Advanced Energy and Original Equipment Manufacturing (OEM). It offers Helium Plasma Generator for delivery of RF energy and helium to cut, coagulate and ablate soft tissue during open and laparoscopic surgical procedures. The company offers Renuvion branded products for the cosmetic surgery market that enable plastic surgeons, fascial plastic surgeons, and cosmetic physicians to provide controlled heat to the tissue to achieve their desired results; and J-Plasma branded products for the hospital surgical market. It also develops, manufactures, and sells disposable hand pieces, and OEM generators and accessories. The company was formerly known as Bovie Medical Corporation and changed its name to Apyx Medical Corporation in January 2019. Apyx Medical Corporation was incorporated in 1982 and is based in Clearwater, Florida.
Insider Transactions at APYX
Insider Transaction List
View all| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Dec 12
2023
|
Matthew C Hill Chief Financial Officer |
BUY
Open market or private purchase
|
Direct |
2,500
+50.0%
|
$5,000
$2.19 P/Share
|
|
Nov 14
2023
|
Charles D. Goodwin Ii Chief Executive Officer |
BUY
Open market or private purchase
|
Direct |
50,000
+35.71%
|
$50,000
$1.57 P/Share
|
|
Jul 12
2023
|
Lawrence Waldman Director |
BUY
Exercise of conversion of derivative security
|
Indirect |
5,338
+50.0%
|
$10,676
$2.97 P/Share
|
|
Jun 26
2023
|
Todd Hornsby Executive Vice President |
SELL
Open market or private sale
|
Direct |
15,000
-99.73%
|
$105,000
$7.56 P/Share
|
|
Jun 26
2023
|
Todd Hornsby Executive Vice President |
BUY
Exercise of conversion of derivative security
|
Direct |
15,000
+50.0%
|
$15,000
$1.77 P/Share
|
|
Jun 06
2023
|
Michael Geraghty Director |
BUY
Exercise of conversion of derivative security
|
Direct |
10,000
+26.67%
|
$20,000
$2.79 P/Share
|
|
Aug 29
2022
|
Charles D. Goodwin Ii Chief Executive Officer |
BUY
Open market or private purchase
|
Direct |
11,750
+12.9%
|
$58,750
$5.95 P/Share
|
|
Jul 11
2022
|
Moshe Citronowicz Sr. V.P. of Operations |
BUY
Exercise of conversion of derivative security
|
Direct |
30,000
+6.17%
|
$60,000
$2.54 P/Share
|
|
Jul 11
2022
|
Lawrence Waldman Director |
BUY
Exercise of conversion of derivative security
|
Direct |
24,000
+38.98%
|
$48,000
$2.54 P/Share
|
|
Jul 06
2022
|
Michael Geraghty Director |
BUY
Exercise of conversion of derivative security
|
Direct |
4,000
+18.6%
|
$8,000
$2.54 P/Share
|
|
Jul 05
2022
|
Andrew Makrides Director |
SELL
Payment of exercise price or tax liability
|
Direct |
13,583
-2.13%
|
$81,498
$6.14 P/Share
|
|
Jul 05
2022
|
Andrew Makrides Director |
BUY
Exercise of conversion of derivative security
|
Direct |
30,000
+4.49%
|
$60,000
$2.54 P/Share
|
|
May 19
2022
|
Lawrence Waldman Director |
BUY
Exercise of conversion of derivative security
|
Direct |
8,000
+37.1%
|
$16,000
$2.79 P/Share
|
|
May 11
2022
|
Michael Geraghty Director |
BUY
Exercise of conversion of derivative security
|
Direct |
6,000
+30.77%
|
$12,000
$2.79 P/Share
|
|
Mar 21
2022
|
Craig A. Swandal Director |
BUY
Exercise of conversion of derivative security
|
Direct |
17,000
+50.0%
|
$68,000
$4.98 P/Share
|
|
Jan 07
2022
|
Craig A. Swandal Director |
BUY
Exercise of conversion of derivative security
|
Direct |
7,173
+10.65%
|
$64,557
$9.42 P/Share
|
|
Mar 08
2021
|
Lawrence Waldman Director |
BUY
Exercise of conversion of derivative security
|
Direct |
5,563
+50.0%
|
$11,126
$2.81 P/Share
|
|
Mar 05
2021
|
Michael Geraghty Director |
BUY
Exercise of conversion of derivative security
|
Direct |
7,500
+50.0%
|
$15,000
$2.81 P/Share
|
Last 12 Months Summary
| Exercise of conversion of derivative security | 30.3K shares |
|---|---|
| Open market or private purchase | 52.5K shares |
| Open market or private sale | 15K shares |
|---|